Participants infectious at day 8 · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.2 to 0.25 mg/kg may leads to lower participants infectious at day 3‐4 compared with no primaquine, with artemisinin partner, (low certainty).
2 findings from 1 review
Participants with severe haemolysis · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.4 to 0.5 mg/kg showed no clear difference in participants with severe haemolysis compared with no primaquine, with artemisinin partner, (low certainty).
1 finding from 1 review
Participants infectious at day 8 · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.75 mg/kg showed no clear difference in participants infectious at day 3‐4 compared with no primaquine, with artemisinin partner, (low certainty).
2 findings from 1 review
Participants with gametocytes at day 3‐4, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.75 mg/kg showed no clear difference in participants with gametocytes at day 3‐4, by PCR compared with no primaquine, with artemisinin partner, (low certainty).
1 finding from 1 review
Participants with gametocytes at day 8, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.75 mg/kg leads to lower participants with gametocytes at day 8, by PCR compared with no primaquine, with artemisinin partner, (high certainty).
1 finding from 1 review
Participants with severe haemolysis · adults and children with malaria being treated with artemisinin combination treatment
1 finding from 1 review
Participants with gametocytes at day 4‐5, by microscopy · adults and children with malaria being treated with non‐artemisinin treatment
Single dose primaquine at 0.4 to 0.5 mg/kg showed no clear difference in participants with gametocytes at day 4‐5, by microscopy compared with no primaquine, with non‐artemisinin partner, (moderate certainty).
1 finding from 1 review
Participants with gametocytes at day 8, by microscopy · adults and children with malaria being treated with non‐artemisinin treatment
Single dose primaquine at 0.4 to 0.5 mg/kg probably leads to lower participants with gametocytes at day 8, by microscopy compared with no primaquine, with non‐artemisinin partner, (moderate certainty).
1 finding from 1 review
Participants infectious at day 8 · adults and children with malaria being treated with non‐artemisinin treatment
It is very uncertain whether single dose primaquine at 0.75 mg/kg changes participants infectious at day 5 compared with no primaquine, with non‐artemisinin partner, (very low certainty).
2 findings from 1 review
Participants with gametocytes at day 5, by microscopy · adults and children with malaria being treated with non‐artemisinin treatment
Single dose primaquine at 0.75 mg/kg showed no clear difference in participants with gametocytes at day 5, by microscopy compared with no primaquine, with non‐artemisinin partner, (low certainty).
1 finding from 1 review
Participants with gametocytes at day 8, by microscopy · adults and children with malaria being treated with non‐artemisinin treatment
Single dose primaquine at 0.75 mg/kg probably leads to lower participants with gametocytes at day 8, by microscopy compared with no primaquine, with non‐artemisinin partner, (moderate certainty).
1 finding from 1 review
Participants with gametocytes at day 3‐4, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.2 to 0.25 mg/kg showed no clear difference in participants with gametocytes at day 3 to 4 by PCR compared with no primaquine, with artemisinin partner, (moderate certainty).
1 finding from 1 review
Participants with gametocytes at day 8, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.2 to 0.25 mg/kg leads to lower participants with gametocytes at day 8 by PCR compared with no primaquine, with artemisinin partner, (high certainty).
1 finding from 1 review
Participants with severe haemolysis · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.2 to 0.25 mg/kg showed no clear difference in participants with severe haemolysis compared with no primaquine, with artemisinin partner, (moderate certainty).
1 finding from 1 review
Participants infectious at day 8 · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.4 to 0.5 mg/kg may leads to lower participants infectious at day 3‐4 compared with no primaquine, with artemisinin partner, (low certainty).
2 findings from 1 review
Participants with gametocytes at day 3‐4, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.4 to 0.5 mg/kg showed no clear difference in participants with gametocytes at day 3‐4, by PCR compared with no primaquine, with artemisinin partner, (moderate certainty).
1 finding from 1 review
Participants with gametocytes at day 8, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.4 to 0.5 mg/kg leads to lower participants with gametocytes at day 8, by PCR compared with no primaquine, with artemisinin partner, (high certainty).
1 finding from 1 review
Parasitological failure At 2 to 2.5 months · patients with treating urinary schistosomiasis
Metrifonate 3 x 7.5 mg/kg given two weeks apart may leads to lower parasitological failure At 2 to 2.5 months compared with placebo (low certainty).
1 finding from 1 review
Mean percent egg reduction At 2 to 2.5 months · patients with treating urinary schistosomiasis
1 finding from 1 review
Parasitological failure At 6 months · patients with treating urinary schistosomiasis
Metrifonate 3 x 7.5 mg/kg given two weeks apart probably leads to lower parasitological failure At 6 months compared with placebo (moderate certainty).
1 finding from 1 review